M Huber

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

Michael Wagner, M Huber, Thomas Berg et al. · Gastroenterology · 2005 · 455 citations

Medicine, Infectious Diseases, Pharmacotherapy +14

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

M VONWAGNER, M Huber, Thomas Berg et al. · Gastroenterology · 2005 · 83 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +14

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

Paul Thoueille, Susana Alves Saldanha, Fabian Schaller et al. · The Lancet Regional Health - Europe · 2023 · 51 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy

Bernard Surial, Frédérique Chammartin, José Damas et al. · Clinical Infectious Diseases · 2023 · 50 citations · Full text

Public Health, Internal Medicine, Pharmacotherapy +16

High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus–coinfected Men Who Have Sex With Men

Dominique L. Braun, Benjamin Hampel, Roger D. Kouyos et al. · Clinical Infectious Diseases · 2018 · 35 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17